Concomitant mutations predict poor prognosis in acute myeloid leukemia patients with double mutant .
作者信息
Tien Feng-Ming, Hou Hsin-An, Tang Jih-Luh, Kuo Yuan-Yeh, Chen Chien-Yuan, Tsai Cheng-Hong, Yao Ming, Lin Chien-Ting, Li Chi-Cheng, Huang Shang-Yi, Ko Bor-Sheng, Hsu Szu-Chun, Wu Shang-Ju, Liu Jia-Hau, Chou Sheng Chieh, Tsay Woei, Tseng Mei-Hsuan, Liu Ming-Chih, Liu Chia-Wen, Lin Liang-In, Chou Wen-Chien, Tien Hwei-Fang
机构信息
Department of Internal Medicine, Division of Hematology, National Taiwan University Hospital.
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University.
出版信息
Haematologica. 2018 Nov;103(11):e510-e513. doi: 10.3324/haematol.2018.189043. Epub 2018 May 17.
Abstract
摘要
相似文献
1
Concomitant mutations predict poor prognosis in acute myeloid leukemia patients with double mutant .伴随突变预示着具有双突变的急性髓系白血病患者预后不良。
Haematologica. 2018 Nov;103(11):e510-e513. doi: 10.3324/haematol.2018.189043. Epub 2018 May 17.
2
CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.CSF3R 突变与伴有 CEBPA 双突变的急性髓系白血病患者的不良预后相关。
Ann Hematol. 2019 Jul;98(7):1641-1646. doi: 10.1007/s00277-019-03699-7. Epub 2019 Apr 30.
3
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.具有CEBPA双突变的核型正常急性髓系白血病患者预后良好，但异基因干细胞移植并不能带来生存获益。
Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4.
4
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.WT1 突变热点的单核苷酸多态性可预测细胞遗传学正常的急性髓系白血病患者的良好预后。
J Clin Oncol. 2010 Feb 1;28(4):578-85. doi: 10.1200/JCO.2009.23.0342. Epub 2009 Dec 28.
5
Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'.对“伴有CEBPA突变的急性髓系白血病中的异质性：仅CEBPA双突变而非单CEBPA突变与良好预后相关”的回复
Br J Cancer. 2009 Aug 18;101(4):738-40. doi: 10.1038/sj.bjc.6605207. Epub 2009 Jul 21.
6
CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.CEBPA 单突变可能是中危细胞遗传学核型伴有 NPM1 和 FLT3-ITD 野生型急性髓系白血病患者的有利预后指标。
Leuk Res. 2013 Nov;37(11):1488-94. doi: 10.1016/j.leukres.2013.08.014. Epub 2013 Sep 5.
7
8
CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.埃及急性髓系白血病患者中的CEBPA基因突变：对预后的影响。
Hematology. 2013 Mar;18(2):61-8. doi: 10.1179/1607845412Y.0000000032. Epub 2012 Sep 14.
9
[NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].儿童细胞遗传学正常的急性髓系白血病中的NPM1和CEBPA突变
Zhonghua Er Ke Za Zhi. 2014 Apr;52(4):303-7.
10
Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.急性髓系白血病中 CCAAT/增强子结合蛋白α（CEBPA）突变和启动子甲基化的联合检测显示出共同的表型特征。
Leuk Res. 2011 Feb;35(2):200-7. doi: 10.1016/j.leukres.2010.09.018. Epub 2010 Oct 20.
引用本文的文献
1
CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.CEBPA 基因突变在急性髓系白血病中的意义：对风险分层和治疗的影响。
Int J Hematol. 2024 Nov;120(5):541-547. doi: 10.1007/s12185-024-03773-5. Epub 2024 Apr 26.
2
mutant variant allele frequency may reflect prognosis in Chinese adult patients with de novo cytogenetically normal acute myeloid leukemia.突变型等位基因频率可能反映中国初诊细胞遗传学正常的成人急性髓系白血病患者的预后。
Biomol Biomed. 2024 Feb 27;24(4):982-989. doi: 10.17305/bb.2024.10244.
3
Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations.免疫和代谢途径失调与 CEBPA bZIP 框内突变的成人急性髓系白血病患者的不良预后相关。
Blood Cancer J. 2024 Jan 23;14(1):15. doi: 10.1038/s41408-023-00975-8.
4
Prognostic impact of CEBPA mutational subgroups in adult AML.CEBPA 突变亚组对成人 AML 的预后影响。
Leukemia. 2024 Feb;38(2):281-290. doi: 10.1038/s41375-024-02140-x. Epub 2024 Jan 16.
5
Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors.2023年急性髓系白血病的现代风险分层：整合既定和新出现的预后因素。
Cancers (Basel). 2023 Jul 6;15(13):3512. doi: 10.3390/cancers15133512.
6
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.散发性和家族性伴有 CEBPA 突变的急性髓系白血病。
Curr Hematol Malig Rep. 2023 Oct;18(5):121-129. doi: 10.1007/s11899-023-00699-3. Epub 2023 Jun 1.
7
A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms.一种调节原发性骨髓增生异常肿瘤临床表现和预测治疗效果的表型轴。
Cancer Res Commun. 2022 Apr 26;2(4):258-276. doi: 10.1158/2767-9764.CRC-21-0194. eCollection 2022 Apr.
8
[Restratifying the prognosis of acute myeloid leukemia patients with CEBPA double mutations based on CSF3R mutations and measurable residual disease].基于CSF3R突变和可测量残留病重新评估伴有CEBPA双突变的急性髓系白血病患者的预后
Zhonghua Xue Ye Xue Za Zhi. 2022 Dec 14;43(12):1021-1027. doi: 10.3760/cma.j.issn.0253-2727.2022.12.008.
9
A pan-cancer landscape of IGF2BPs and their association with prognosis, stemness and tumor immune microenvironment.IGF2BPs的泛癌图谱及其与预后、干性和肿瘤免疫微环境的关联。
Front Oncol. 2023 Jan 4;12:1049183. doi: 10.3389/fonc.2022.1049183. eCollection 2022.
10
Acute Myeloid Leukemia With Mutations: Current Progress and Future Directions.伴有突变的急性髓系白血病：当前进展与未来方向
Front Oncol. 2022 Feb 1;12:806137. doi: 10.3389/fonc.2022.806137. eCollection 2022.
本文引用的文献
1
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.伴有CEBPA突变的急性髓系白血病患者中GATA2突变的临床影响：AML研究组的一项研究
Leukemia. 2016 Nov;30(11):2248-2250. doi: 10.1038/leu.2016.185. Epub 2016 Jul 4.
2
Genomic Classification and Prognosis in Acute Myeloid Leukemia.急性髓系白血病的基因组分类与预后
N Engl J Med. 2016 Jun 9;374(23):2209-2221. doi: 10.1056/NEJMoa1516192.
3
Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.老年急性髓系白血病患者的遗传改变及其临床意义。
Leukemia. 2016 Jul;30(7):1485-92. doi: 10.1038/leu.2016.65. Epub 2016 Mar 17.
4
Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.CEBPA 突变 AML 的化疗基因组学研究揭示了 CSF3R 突变的复发性和亚组对 JAK 抑制剂的敏感性。
Blood. 2016 Jun 16;127(24):3054-61. doi: 10.1182/blood-2016-03-705053. Epub 2016 Mar 31.
5
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.剪接因子突变预示着初发急性髓系白血病患者的预后不良。
Oncotarget. 2016 Feb 23;7(8):9084-101. doi: 10.18632/oncotarget.7000.
6
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.具有CEBPA双突变的核型正常急性髓系白血病患者预后良好，但异基因干细胞移植并不能带来生存获益。
Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4.
7
The role of different genetic subtypes of CEBPA mutated AML.CEBPA 基因突变的不同基因亚型在 AML 中的作用。
Leukemia. 2014 Apr;28(4):794-803. doi: 10.1038/leu.2013.273. Epub 2013 Sep 23.
8
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.318 例初发非 M3 急性髓系白血病患者细胞遗传学和分子改变与危险分层的整合。
Leukemia. 2014 Jan;28(1):50-8. doi: 10.1038/leu.2013.236. Epub 2013 Aug 9.
9
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.伴有双突变 CEBPA 的预后良好的急性髓系白血病中异体和自体造血干细胞移植的价值。
Blood. 2013 Aug 29;122(9):1576-82. doi: 10.1182/blood-2013-05-503847. Epub 2013 Jul 17.
10
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.CEBPA 双突变急性髓系白血病在伴有 TET2 和 GATA2 改变的病例中，有 76.8% 同时存在分子突变，这些突变影响预后。
Br J Haematol. 2013 Jun;161(5):649-658. doi: 10.1111/bjh.12297. Epub 2013 Mar 25.
Zotero 插件